Table 1 Associations between E2F1, EZH2, SUZ12 and CEBPD expression levels with important clinicopathologic variables in two independent data sets

Associations between E2F1, EZH2, SUZ12 and CEBPD expression levels and clinical variables in 80 prostate cancers and paired non-tumor tissues
Parameters	Category	Case no.	E2F1 LI		EZH2 LI		SUZ12 LI		CEBPD LI
			H-score	P -value	H-score	P -value	H-score	P -value	H-score	P -value
Tissue type	Non-tumor	80	130.6±17.27	<0.001^a	144.5±22.59	<0.001^a	122.9±11.13	<0.001^a	323.3±25.37	<0.001^a
	Tumor	80	225.9±41.34		258.8±38.89		228.9±44.59		206.9±51.01
Tumor stage	Stages I–IIA	19	199.0±26.49	0.002^a	226.1±27.01	<0.001^a	193.4±16.75	<0.001^a	270.3±42.34	<0.001^a
	Stage≥IIB	61	234.3±41.69		268.9±36.45		240.0±44.82		187.1±34.92

Associations between E2F1, EZH2, SUZ12 and CEBPD expression levels and tumor metastasis in 15 pairs of primary and metastatic prostate cancers
Parameters	Category	Case no.	E2F1 LI		EZH2 LI		SUZ12 LI		CEBPD LI
			H-score	P -value	H-score	P -value	H-score	P -value	H-score	P -value
Tumor status	Primary	15	272.7±30.81	<0.001^a	271.3±36.47	0.002^a	293.0±16.78	<0.001^a	267.3±39.68	<0.001^a
	Metastatic	15	329.3±35.25		310.3±24.96		335.7±24.56		167.0±23.28

Quick links

Search